These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 8270970

  • 1. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G.
    J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF.
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [Abstract] [Full Text] [Related]

  • 3. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE.
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [Abstract] [Full Text] [Related]

  • 4. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 5. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.
    Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, McCloskey T.
    J Clin Oncol; 1994 Jan; 12(1):176-83. PubMed ID: 8270975
    [Abstract] [Full Text] [Related]

  • 6. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
    Schlaifer D, Attal M, Huguet F, Canal P, Laurent G, Pris J.
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):31. PubMed ID: 8073306
    [No Abstract] [Full Text] [Related]

  • 7. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C.
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP, Kris E, Vose J, Bierman PJ, Gwilt P, Armitage JO.
    J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
    [Abstract] [Full Text] [Related]

  • 9. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
    Mulder PO, Sleijfer DT, Willemse PH, de Vries EG, Uges DR, Mulder NH.
    Cancer Res; 1989 Aug 15; 49(16):4654-8. PubMed ID: 2545349
    [Abstract] [Full Text] [Related]

  • 10. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L.
    J Clin Oncol; 1997 Feb 15; 15(2):491-8. PubMed ID: 9053470
    [Abstract] [Full Text] [Related]

  • 11. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
    Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R.
    Cancer Res; 1993 Oct 15; 53(20):4850-4. PubMed ID: 8402672
    [Abstract] [Full Text] [Related]

  • 12. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P.
    J Clin Oncol; 1995 Mar 15; 13(3):596-602. PubMed ID: 7884421
    [Abstract] [Full Text] [Related]

  • 13. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF.
    J Clin Oncol; 1991 Oct 15; 9(10):1871-9. PubMed ID: 1919637
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct 15; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 15. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS.
    Biol Blood Marrow Transplant; 2011 Jul 15; 17(7):987-94. PubMed ID: 20965266
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D, Vassal G, Pondarré C, Bonnay M, Benhamou E, Couanet D, Plantaz D, Hartmann O.
    Bone Marrow Transplant; 1996 Apr 15; 17(4):485-9. PubMed ID: 8722343
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct 15; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.